Home Cart Sign in  
Chemical Structure| 851524-96-4 Chemical Structure| 851524-96-4

Structure of 6-Aminopyridine-3-boronic acid
CAS No.: 851524-96-4

Chemical Structure| 851524-96-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 851524-96-4 ]

CAS No. :851524-96-4
Formula : C5H7BN2O2
M.W : 137.93
SMILES Code : NC1=NC=C(C=C1)B(O)O
MDL No. :MFCD09907980
InChI Key :NPJBPJIQMCHZLJ-UHFFFAOYSA-N
Pubchem ID :22396308

Safety of [ 851524-96-4 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H332-H335
Precautionary Statements:P261-P280-P305+P351+P338

Computational Chemistry of [ 851524-96-4 ] Show Less

Physicochemical Properties

Num. heavy atoms 10
Num. arom. heavy atoms 6
Fraction Csp3 0.0
Num. rotatable bonds 1
Num. H-bond acceptors 3.0
Num. H-bond donors 3.0
Molar Refractivity 38.47
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

79.37 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

0.0
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

-0.59
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

-1.65
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

-1.57
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-1.86
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

-1.13

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-0.7
Solubility 27.4 mg/ml ; 0.199 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-0.61
Solubility 34.2 mg/ml ; 0.248 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-0.53
Solubility 40.9 mg/ml ; 0.296 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

No
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

No
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-7.56 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

1.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

1.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

2.06

Application In Synthesis of [ 851524-96-4 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 851524-96-4 ]

[ 851524-96-4 ] Synthesis Path-Downstream   1~3

  • 1
  • [ 851524-96-4 ]
  • [ 1798-85-2 ]
  • 5-(3-cyclopropylphenyl)pyridin-2-amine [ No CAS ]
YieldReaction ConditionsOperation in experiment
37% With tetrakis(triphenylphosphine) palladium(0); caesium carbonate; In 1,4-dioxane; water; at 90℃; for 16h;Inert atmosphere; Monomer Synthesis Procedure A 1-Bromo-3-cyclopropylbenzene (0.20 g, 1.4 mmol, 1.0 eq.), 6- Aminopyridine-3-boronic acid (0.28 g, 1 .4 mmol, 1 .0 eq.) and C52C03 (1 .41g, 4.3 mmol, 1 .5 eq.) were added to a mixture of dioxane (8 mL) and water (2 mL) which was subsequently degassed with argon for 30 mi Pd(PPh3)4 (0.087 g, 4.3 mmol, 0.05 eq.) was added and the reaction mixture was heated to 90 C for 16 h. After completion of the reaction, the reaction mixture was filtered and the filtrate was concentrated under reducedpressure. The resulting crude material was dissolved in ethyl acetate (100 mL) and washed with cold water (100 mL) and brine (25 mL). The organic layer was dried over Na2504 and concentrated under reduced pressure to obtain crude product. This material was purified by flash chromatography (over silica gel 100-200 mesh) eluting with 25 % ethyl acetate in petroleumether to obtain pure 5-(3-cyclopropylphenyl)pyridin-2-amine (80 mg; 37%).
  • 2
  • [ 851524-96-4 ]
  • [ 84539-22-0 ]
  • 5-(2-morpholinopyrimidin-5-yl)pyridin-2-amine [ No CAS ]
YieldReaction ConditionsOperation in experiment
With tetrakis(triphenylphosphine) palladium(0); potassium carbonate; In 1,4-dioxane; water; at 85℃; for 16h; To a solution of 4-(5-bromopyrimidin-2-yl)mo holine (5.5 g, 22.53 mmol), (6-aminopyridin-3- yl)boronic acid (5 g, 36.2 mmol), K2C03 (9.34 g, 67.6 mmol) and Pd(PPh3)4 (1.302 g, 1.127 mmol) in 1,4-dioxane (150 mL) and water (75 mL) was heated to about 85 C and stirred for aboutl6 h. The reaction mixture was cooled to rt and filtered. Water was added and a precipitate formed. EtOAc was added and the solid remaining between the phases was collected by filtration, washed with water and EtOAc, and dried under vacuum to give the title compound (3.52 g, 61%). The organic phase from the filtrate was separated and the aqueous phase was extracted once more with EtOAc. The organics were combined, dried over MgSO/i, filtered and concentrated in vacuo to give crude product. The residue was purified by flash-column chromatography on silica gel (2 M NH3 in MeOH/DCM 0-15%) to afford additional title compound (0.69 g, 12%); LC/MS (Table 1, Method e) P = 0.67 min; MS m/z: 258 (M+ H)+
  • 3
  • [ 851524-96-4 ]
  • [ 84539-22-0 ]
  • 2-(2-morpholinopyrimidin-5-yl)-7,8-dihydrobenzo[4,5]imidazo[1,2-a]pyridin-9(6H)-one [ No CAS ]
 

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 851524-96-4 ]

Organoborons

Chemical Structure| 903513-62-2

A207117 [903513-62-2]

(2-Aminopyridin-4-yl)boronic acid

Similarity: 0.84

Chemical Structure| 659742-21-9

A216887 [659742-21-9]

(6-Methylpyridin-3-yl)boronic acid

Similarity: 0.75

Chemical Structure| 223463-14-7

A113198 [223463-14-7]

(6-Bromopyridin-3-yl)boronic acid

Similarity: 0.74

Chemical Structure| 913835-63-9

A175402 [913835-63-9]

Imidazo[1,2-a]pyridine-6-boronic acid

Similarity: 0.73

Chemical Structure| 444120-91-6

A180503 [444120-91-6]

(6-Chloropyridin-3-yl)boronic acid

Similarity: 0.73

Amines

Chemical Structure| 903513-62-2

A207117 [903513-62-2]

(2-Aminopyridin-4-yl)boronic acid

Similarity: 0.84

Chemical Structure| 827614-64-2

A104258 [827614-64-2]

5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine

Similarity: 0.73

Chemical Structure| 1036991-24-8

A268925 [1036991-24-8]

N,N-Dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine

Similarity: 0.67

Chemical Structure| 1032758-99-8

A341611 [1032758-99-8]

3-Chloro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine

Similarity: 0.61

Chemical Structure| 850568-25-1

A251003 [850568-25-1]

(4-(Pyridin-2-ylcarbamoyl)phenyl)boronic acid

Similarity: 0.59

Related Parent Nucleus of
[ 851524-96-4 ]

Pyridines

Chemical Structure| 903513-62-2

A207117 [903513-62-2]

(2-Aminopyridin-4-yl)boronic acid

Similarity: 0.84

Chemical Structure| 659742-21-9

A216887 [659742-21-9]

(6-Methylpyridin-3-yl)boronic acid

Similarity: 0.75

Chemical Structure| 223463-14-7

A113198 [223463-14-7]

(6-Bromopyridin-3-yl)boronic acid

Similarity: 0.74

Chemical Structure| 444120-91-6

A180503 [444120-91-6]

(6-Chloropyridin-3-yl)boronic acid

Similarity: 0.73

Chemical Structure| 827614-64-2

A104258 [827614-64-2]

5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine

Similarity: 0.73